Clinical trial · Observational
Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours
A Study Evaluating The Clinical Utility Of The Health-Related Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours QUALINETS Study
NCT02853422CI-TRIAL-00048138QUALINETScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the utility of the QLQ-GINET21 in making clinical and therapeutic decisions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Neuroendocrine Tumours | Digestive System Neuroendocrine Tumor | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Survey on the clinical utility of the QLQ-GINET21, which the investigator is to complete for each patient enrolled
- timeFrame
- Day 1
Secondary outcomes (7)
- measure
- Socio-demographic variables of the investigator
- timeFrame
- Day 1
- description
- Descriptive analysis of socio-demographic variables including age, gender, years of experience in treating neuroendocrine tumours (NETs), area of professional activity, capacity of the hospital
- measure
- Socio-demographic variables of the patient
- timeFrame
- Day 1
- description
- Descriptive analysis of socio-demographic variables including age, gender, employment status, marital status, educational level
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with a diagnosis of gastrointestinal endocrine tumour. * Patient able to read and understand the study questionnaires. * Patient who has given informed consent in writing to take part in the study. Exclusion Criteria: * Patient who is taking part in another clinical study during the study. * Patients with another serious malignancy. * Patients unable to meet the requirements of the protocol (non-compliant patients or those unfit to answer the questionnaires).
References
Publications (0)
Data not yet available
No reference posted for this study.